{"database": "press", "table": "releases", "rows": [["https://www.gallego.senate.gov/news/press-releases/gallego-continues-to-push-for-answers-on-trumps-pharmaceutical-deals/", "Gallego Continues to Push for Answers on Trump\u2019s Pharmaceutical Deals", "2025-12-22", "2025", "2025-12", "Democrat", "Senate", "AZ", "Ruben Gallego", "G000574", "www.gallego.senate.gov", "gallego", "https://www.gallego.senate.gov/newsroom/press-releases/", "scraper", "In letters to the drug companies who recently inked deals with President Trump, Senator Gallego calls for more details and greater transparency\n\nWASHINGTON \u2013 In response to President Trump\u2019s recent announcement that nine drugmakers agreed to direct-to-consumer pricing through the TrumpRx drug purchasing platform, and the implementation of \u201cMost Favored Nation\u201d (MFN) pricing in Medicaid, Senator Ruben Gallego (D-AZ) called on the drug manufacturers to clarify the agreement and provide the public with details on the arrangement.\n\n\u201cIt raises concern that to date, the public has been provided with only limited details, despite the significance of this arrangement for millions of patients, and that in return for this arrangement [these companies] will get a three-year exemption from Section 232 tariffs,\u201d Senator Gallego wrote in the letters to the drug manufacturers.\n\nIn the letters, Senator Gallego asks the drug manufacturers the following questions:\n\nUnder the proposed model, which countries and pricing metrics will be used in the MFN formula?\n\nWill [the company] commit to transparency in how MFN prices are calculated, and disclose how the final MFN price is calculated, whether discounts, rebates, or pricing agreements are incorporated?\n\nHow frequently will MFN comparator pricing be updated? Will changes be made automatically as international pricing data changes?\n\nWhat is the full scope of [your company\u2019s] drugs subject to MFN pricing in Medicaid?\n\nHow will MFN pricing in Medicaid affect Medicaid Best Price and the Medicaid Drug Rebate Program?\n\nWill [your company] commit to not shifting costs to other markets? Do you commit to not recoup any revenue reductions by raising prices in private insurance markets, employee-sponsored plans, or Medicare?\n\nAre there plans for [the company] to expand MFN or TrumpRx-style pricing to the commercial insurance or Medicare Part D markets?\n\nGiven that Medicaid beneficiary cost-sharing on prescription drugs is generally limited, please explain how beneficiaries will see savings under this arrangement.\n\nAs currently described, this model would require patients to bypass their insurance and pay cash for medications \u2014 often at high out-of-pocket costs. Given that many insured patients already have lower copays or coinsurance than the proposed TrumpRx discounts, it is unclear how this platform would provide meaningful relief. In fact, it may increase costs for patients,\u201d Senator Gallego concludes the letters.\n\nSenator Gallego sent the letters to the nine companies included in President Trump\u2019s most recent announcement. These companies include:\n\nAmgen\n\nBoehringer Ingelheim\n\nBristol Myers Squibb\n\nGenentech\n\nGilead Sciences\n\nGSK\n\nNovartis\n\nMerck\n\nSanofi", 1, "2026-03-30T01:40:41Z", "2026-04-06T20:09:11Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.gallego.senate.gov/news/press-releases/gallego-continues-to-push-for-answers-on-trumps-pharmaceutical-deals/"], "units": {}, "query_ms": 2.0508950110524893, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}